Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Sectoral/ Thematic median (248 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 17 Jul 2025 – 20 Aug 2026, limited by HDFC Innovation Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | HDFC Innovation Fund | Nifty 500 |
|---|---|---|
| 17 Jul 2025 | ₹100.00 | ₹100.00 |
| 19 Aug 2025 | ₹101.08 | ₹98.49 |
| 22 Sep 2025 | ₹104.12 | ₹99.84 |
| 25 Oct 2025 | ₹103.84 | ₹101.14 |
| 27 Nov 2025 | ₹103.81 | ₹102.25 |
| 30 Dec 2025 | ₹101.52 | ₹101.06 |
| 02 Feb 2026 | ₹97.47 | ₹97.51 |
| 07 Mar 2026 | ₹96.47 | ₹95.99 |
| 09 Apr 2026 | ₹96.39 | ₹94.10 |
| 12 May 2026 | ₹100.99 | ₹95.22 |
| 15 Jun 2026 | ₹105.27 | ₹97.74 |
| 18 Jul 2026 | ₹111.07 | ₹99.64 |
| 20 Aug 2026 | ₹118.69 | ₹100.40 |
| Metric | HDFC · Regular · IDCW NAV ₹11.88 Very High risk ★★★★★ 1Y | Category median Sectoral/ Thematic · 248 funds |
|---|---|---|
| +17.24% | +3.54% | |
| — | +11.47% | |
| — | +9.70% | |
| — | +10.32% | |
| +16.98% | +9.15% | |
| +28.21% | — | |
| — | +12.10% | |
| — | +10.32% | |
| — | +8.80% | |
| Risk | ||
| 14.18% | 15.91% | |
| 0.76 | 0.25 | |
| 1.07 | 0.32 | |
| -12.75% | -26.14% | |
| Nifty 500 | — | |
| — | -0.04% | |
| — | 0.98 | |
| — | 98.3% | |
| — | 101.5% | |
| 2.10% | 2.38% | |
| ₹2,632Cr | ₹1,160Cr | |
| 1.00% | — | |
| None | — | |
| ₹100 | — | |
| ₹141 | — | |
| 11% | 42% | |
| Dhruv Muchhal | — | |
| 17 Jul 2025 | — | |
| 62 | — | |
| 42.2% | — | |
| 1.4% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.